Novel Biomarkers Related Xuebijing Injection Improves Sepsis

Southeast University, China

Status: Not yet enrolling

Conditions: Sepsis

Study type: Observational

Funder types: Other

Identifiers

NCT06920420

82472202 (Other Grant/Funding Number)

2024ZDSYLL513-P01

Details and patient eligibility

About

Sepsis is a life-threatening clinical syndrome of organ dysfunction caused by dysregulation of the body's response to infection, and is a common cause of ICU admission for critically ill patients, posing a serious threat to human health. The study demonstrated that hemopexin injection significantly reduced the 28-day all-cause mortality rate of sepsis patients, and this study clarified the specific target and molecular mechanism of hemopexin injection in the treatment of sepsis, which may be of great scientific significance and clinical value for the precise treatment of sepsis and the research and development of new drugs.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Meeting the Sepsis 3.0 diagnostic criteria;
2. SOFA score ≥ 2 and < 13;
3. Signed informed consent.

Exclusion criteria

1. Age <18 years or >75 years;
2. Pregnant or lactating women;
3. Presence of severe primary diseases including malignant tumors severe hematologic disorders and HIV infection;
4. Current use of immunosuppressants or history of organ transplantation within the past 6 months;
5. Comorbidities that significantly affect vascular endothelial structure and function such as acute myocardial infarction.

Trial design

30 participants in 3 patient groups

Xuebijing treatment group

Description:

Based on the standard treatment group Xuebijing injection was added.

Standard treatment group

Description:

Patients with sepsis are given standard treatment according to international guidelines for the management of sepsis and septic shock

Healthy Volunteer Group